P3 Health Partners Signals Turnaround In Earnings Call

P3 Health Partners Inc. ((PIII)) has held its Q1 earnings call. Read on for the main highlights of the call.

P3 Health Partners’ latest earnings call struck a cautiously upbeat tone, as management showcased a sharp swing to positive adjusted EBITDA, stronger Medicare Advantage funding, and tighter provider alignment. However, they were equally clear about ongoing execution risks, high medical loss ratios, and the need for continued capital discipline to sustain the improving trajectory.

Adjusted EBITDA Turnaround

P3 delivered $26 million of adjusted EBITDA in Q1 2026, a dramatic reversal from a $22 million loss a year earlier and ahead of internal plans. Management framed this as proof that structural changes to contracts and care models are starting to translate into tangible operating leverage.

Raised Full-Year 2026 Outlook

On the back of the strong quarter, the company raised full‑year 2026 adjusted EBITDA guidance to a range of $20 million to $60 million, with a midpoint of $40 million. The wide range reflects both management’s increased confidence in the model and recognition of remaining volatility in claims and cost trends.

Improved Medicare Advantage Funding

Per-member funding for the Medicare Advantage book rose about 15% year over year, supported by better rates and restructured payer contracts. This funding lift is central to P3’s thesis that its model can generate sustainable margins even in a challenging Medicare environment.

Delegation and Network Alignment

Delegated functions now cover roughly 63% of membership, giving P3 greater control over care management and claims. Tier 1 provider concentration climbed to 62% from 56% last year, tightening clinical integration and supporting more predictable medical costs.

Medical Margin Strength and Cost Discipline

In Q1, P3 posted a medical margin of $74 million while keeping adjusted operating expenses to $25 million, underscoring improved unit economics. Management stressed that spending remains focused on frontline clinical capabilities, pairing selective investment with ongoing overhead efficiency.

Impact of Favorable Claims Development

The quarter’s headline profitability benefited significantly from about $17 million of favorable prior‑year development and payer settlements. Management broke this down as roughly 65% reserve releases and 35% settlements, acknowledging that such items are inherently non‑recurring and add noise to results.

Flat Medical Trend Versus Industry

P3’s Q1 Medicare Advantage medical expense trend was roughly flat versus its already low 2025 baseline, which ran under 2%. That compares favorably with industry commentary pointing to trends north of 7%, positioning P3 as a relative outlier on cost control.

Capital Structure and Balance Sheet Moves

The company completed the conversion of roughly $250 million of debt into preferred equity and has already issued $30 million of a planned up‑to‑$70 million preferred raise. These steps materially improve stockholders’ equity and market listing compliance, though cash on hand remained modest at $25 million.

Platform Scale and New Partnerships

P3 now manages around 135,000 lives, including 106,000 at‑risk members and approximately 29,000 under management service arrangements. A Nebraska partnership added roughly 28,600 lives, illustrating a disciplined approach to growth that prioritizes delegated structures and better economics.

Deliberate Decline in At-Risk Membership

At‑risk membership slipped about 10% year over year to roughly 106,000, as P3 intentionally exited contracts that failed to meet economic thresholds. While this reduces scale in the near term, management framed the move as crucial to improving margin quality and capital efficiency.

Underlying Earnings Sensitivity

Of the $26 million in Q1 adjusted EBITDA, management estimates about $8 million reflects underlying performance after excluding prior‑year development and settlements. This highlights the company’s sensitivity to reserve movements and reinforces why investors should focus on normalized trends.

Elevated Medical Loss Ratio

Even with improving operations, P3’s adjusted medical loss ratio for the quarter stood at 85.2%, underscoring still‑high claims intensity. Management argued that deeper delegation and better network alignment should gradually push this ratio down, but acknowledged that progress will be uneven.

Liquidity Constraints and Financing Reliance

With only $25 million of cash at quarter‑end, P3 remains reliant on capital structure actions to support its turnaround. Recent debt‑to‑preferred conversions and preferred equity issuances have eased solvency concerns, yet liquidity remains a key watch point for investors.

Execution on Delegation Strategy

The company’s performance increasingly hinges on expanding delegated contracts, now at 63% of membership, which provide greater control over medical costs. Management outlined a multi‑year, stair‑step path to deeper delegation, noting this long runway introduces execution and counterpart risk.

Guidance Variability and Part D Headwinds

The 2026 adjusted EBITDA guidance band of $20 million to $60 million reflects normal variability in claims development and cost trends, including potential surprises. While P3 has reduced its Part D exposure, management cautioned that remaining pharmacy dynamics could still pressure MLRs as members hit out‑of‑pocket caps.

Forward-Looking Outlook

Looking ahead, management’s raised guidance to $20 million–$60 million in adjusted EBITDA for 2026 signals confidence that Q1 momentum can carry through the year. The outlook assumes stable medical trends near recent levels, continued progress on delegation, and successful execution of cost initiatives amid normal claims volatility.

P3 Health Partners’ earnings call painted a picture of a business moving decisively in the right direction, but still in the midst of a complex turnaround. Investors will be watching whether strong Q1 metrics, improved funding, and capital restructuring can translate into durable margins and a stronger balance sheet over the next several years.